Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants

Trial Profile

Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Rotavirus vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 08 Sep 2016 Planned primary completion date changed from 1 Aug 2017 to 1 May 2018.
    • 08 Sep 2016 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top